Decoding the HRD Puzzle: Enhancing Precision Oncology Through Expanded Genomic Profiling-April 2, 2026

Why It Matters

Integrating HRD analysis into a single, FDA‑cleared panel accelerates biomarker‑driven treatment selection, improving outcomes for ovarian cancer patients and setting a benchmark for comprehensive cancer genomics.

Key Takeaways

• Labcorp adds integrated HRD analysis to OmniSeq INSIGHT using Illumina TSO500.
• Genomic scars like LOH, TAI, LST predict platinum and PARP response.
• New HR‑proficient/RB1‑high ovarian subtype shows poor outcomes and high aneuploidy.
• Expanded profiling supports treatment decisions for both HR‑deficient and HR‑proficient tumors.
• Webinar highlights growing demand for comprehensive molecular testing in gynecologic cancers.

Pulse Analysis

Homologous recombination deficiency (HRD) has become a cornerstone biomarker in ovarian cancer, guiding the use of platinum agents and PARP inhibitors. By measuring DNA repair failures through genomic scars—loss of heterozygosity, telomeric allelic imbalance, and large‑scale state transitions—clinicians can predict which tumors are most likely to respond to these targeted therapies. The HRD concept also fuels research into resistance mechanisms, prompting a deeper look at tumor biology beyond traditional histology.

Labcorp’s enhanced OmniSeq INSIGHT leverages Illumina’s TSO500 platform to deliver a unified report that combines standard oncogenic alterations with a robust HRD score. This integration streamlines workflow, reduces turnaround time, and eliminates the need for separate assays. The test also flags the emerging HR‑proficient/RB1‑high subtype, a group characterized by high aneuploidy and unfavorable prognosis, signaling that patients without classic HRD may still benefit from alternative therapeutic strategies. By providing a comprehensive molecular snapshot, the assay equips oncologists with actionable data for both HR‑deficient and HR‑proficient disease.

The broader market is responding to this shift toward all‑inclusive genomic panels. As payers and regulators increasingly demand evidence of clinical utility, platforms that combine multiple biomarkers into a single, reimbursable test gain a competitive edge. Labcorp’s move reflects a growing industry trend: expanding the scope of precision oncology to capture diverse molecular phenotypes, thereby improving patient stratification and fostering next‑generation clinical trials. For providers, the ability to order one test that informs chemotherapy, PARP eligibility, and emerging targeted options simplifies decision‑making and accelerates personalized care.